Boyd Watterson Asset Management LLC OH trimmed its stake in shares of Zimmer Biomet Holdings Inc (NYSE:ZBH) by 20.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 4,250 shares of the medical equipment provider’s stock after selling 1,092 shares during the period. Boyd Watterson Asset Management LLC OH’s holdings in Zimmer Biomet were worth $513,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in ZBH. BlackRock Inc. increased its position in Zimmer Biomet by 4.1% in the 2nd quarter. BlackRock Inc. now owns 17,419,463 shares of the medical equipment provider’s stock worth $2,236,657,000 after purchasing an additional 679,080 shares during the last quarter. Vanguard Group Inc. boosted its stake in Zimmer Biomet by 2.6% during the 2nd quarter. Vanguard Group Inc. now owns 13,380,517 shares of the medical equipment provider’s stock valued at $1,718,057,000 after purchasing an additional 339,106 shares during the period. Longview Partners Guernsey LTD boosted its stake in Zimmer Biomet by 17.7% during the 3rd quarter. Longview Partners Guernsey LTD now owns 7,506,684 shares of the medical equipment provider’s stock valued at $878,958,000 after purchasing an additional 1,128,973 shares during the period. Nordea Investment Management AB boosted its stake in Zimmer Biomet by 7.3% during the 3rd quarter. Nordea Investment Management AB now owns 5,277,660 shares of the medical equipment provider’s stock valued at $617,961,000 after purchasing an additional 357,302 shares during the period. Finally, Jana Partners LLC boosted its stake in Zimmer Biomet by 16.6% during the 3rd quarter. Jana Partners LLC now owns 4,662,497 shares of the medical equipment provider’s stock valued at $545,932,000 after purchasing an additional 662,497 shares during the period. 85.92% of the stock is owned by institutional investors and hedge funds.

Zimmer Biomet Holdings Inc (ZBH) traded down $1.66 during midday trading on Thursday, reaching $122.53. The company had a trading volume of 1,956,600 shares, compared to its average volume of 1,490,986. The company has a quick ratio of 0.78, a current ratio of 1.47 and a debt-to-equity ratio of 0.88. The firm has a market capitalization of $24,760.00, a P/E ratio of 38.17, a price-to-earnings-growth ratio of 1.96 and a beta of 1.15. Zimmer Biomet Holdings Inc has a 1-year low of $108.03 and a 1-year high of $133.49.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings results on Wednesday, November 1st. The medical equipment provider reported $1.72 EPS for the quarter, missing the Zacks’ consensus estimate of $1.74 by ($0.02). The firm had revenue of $1.82 billion for the quarter, compared to the consensus estimate of $1.83 billion. Zimmer Biomet had a net margin of 5.43% and a return on equity of 3.82%. The business’s revenue was down .8% compared to the same quarter last year. During the same period last year, the company posted $1.79 EPS. sell-side analysts anticipate that Zimmer Biomet Holdings Inc will post 8.03 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Monday, January 29th. Investors of record on Friday, December 29th will be given a $0.24 dividend. The ex-dividend date of this dividend is Thursday, December 28th. This represents a $0.96 annualized dividend and a yield of 0.78%. Zimmer Biomet’s payout ratio is 29.91%.

A number of analysts have commented on the company. Jefferies Group reiterated a “buy” rating and issued a $136.00 price objective on shares of Zimmer Biomet in a research report on Friday, November 3rd. Stifel Nicolaus reiterated a “hold” rating and issued a $120.00 price objective on shares of Zimmer Biomet in a research report on Friday, November 3rd. SunTrust Banks reiterated a “buy” rating and issued a $136.00 price objective on shares of Zimmer Biomet in a research report on Monday, October 2nd. TheStreet downgraded Zimmer Biomet from a “b-” rating to a “c+” rating in a research report on Friday, November 24th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Zimmer Biomet in a report on Friday, January 5th. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $137.42.

WARNING: This report was posted by Watch List News and is the property of of Watch List News. If you are viewing this report on another website, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this report can be accessed at https://www.watchlistnews.com/boyd-watterson-asset-management-llc-oh-has-513000-stake-in-zimmer-biomet-holdings-inc-zbh/1803168.html.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings Inc (NYSE:ZBH).

Institutional Ownership by Quarter for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.